Scynexis

Contributing Author

Recent Articles by Scynexis

Sep-28	SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 SCYX +5.24% GlobeNewswire
Sep-22	SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors SCYX +10.45% GlobeNewswire
Sep-15	SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development SCYX GlobeNewswire
Sep-10	SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer SCYX GlobeNewswire
Sep-01	SCYNEXIS to Participate in Upcoming Investor Conferences SCYX GlobeNewswire
Aug-25	SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SCYX SCYX +9.25% GlobeNewswire
Aug-10	SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update SCYX SCYX -6.21% GlobeNewswire
Jun-30	SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) SCYX +5.17% GlobeNewswire
May-22	SCYNEXIS Announces One-for-Eight Reverse Stock Split SCYX SCYX -6.88% GlobeNewswire
May-11	SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update SCYX -10.00% SCYX -5.35% GlobeNewswire
May-06	SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SCYX GlobeNewswire
Mar-31	SCYNEXIS Announces $40.0 Million Private Placement SCYX +16.11% GlobeNewswire
Mar-31	SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) SCYX +16.11% GlobeNewswire
Mar-04	SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update SCYX GlobeNewswire
Feb-26	SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 SCYX GlobeNewswire
Jan-28	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) SCYX GlobeNewswire
Jan-21	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 SCYX GlobeNewswire
Dec-22	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement SCYX GlobeNewswire
Nov-19	SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK SCYX GlobeNewswire
Nov-17	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections SCYX GlobeNewswire
Nov-05	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update SCYX SCYX -5.48% GlobeNewswire
Oct-15	SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study SCYX GlobeNewswire
Sep-30	SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) SCYX -26.67% GlobeNewswire
Sep-04	SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) SCYX GlobeNewswire
Aug-25	SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025 SCYX GlobeNewswire
Aug-13	SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update SCYX SCYX -5.15% GlobeNewswire
May-28	SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study SCYX +28.04% GlobeNewswire
May-15	SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update SCYX SCYX -19.29% GlobeNewswire

Scynexis

Recent Articles by Scynexis

Upgrade your Finviz experience